Gilead Sciences, Inc. (ETR:GIS)

Market Cap	125.09B
Revenue (ttm)	24.58B
Net Income (ttm)	5.37B
Shares Out	n/a
EPS (ttm)	4.27
PE Ratio	23.28
Forward PE	13.86
Dividend	2.82 (2.79%)
Ex-Dividend Date	Sep 15, 2025

Volume	1,575
Average Volume	695
Open	101.40
Previous Close	101.02
Day's Range	100.78 - 102.22
52-Week Range	76.93 - 111.84
Beta	0.35
RSI	64.06
Earnings Date	Nov 6, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: GIS

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD